CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics is a Shanghai-based, Hong Kong-listed (HKEX: 2171) CAR-T developer working across blood cancers, solid tumours and autoimmune disease. Its Claudin18.2-targeted satri-cel (CT041) is approved in China, and adjuvant gastric-cancer results were presented at ESMO 2026.
| Headquarters | Shanghai, China |
|---|---|
| Listing | HKEX:02171 |
| Lead asset / stage | satricabtagene autoleucel (satri-cel; CT041) Approved — China |
| Latest event | CARsgen presented satri-cel adjuvant gastric-cancer results at ESMO Congress 2026. |